+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

R

Actively Recruiting

This study aims to collect prospective safety and effectiveness data for the C-Brace System, a microprocessor-controlled knee ankle foot orthosis, following standard care practices. The research focuses on patients with lower extremity pareses who are fitted with the C-Brace device. The goal is to better understand how the C-Brace influences walking speed, balance, risk of falling, and confidence in balance over time. The C-Brace is a custom-made device with thigh, calf, and foot components connected by an ankle joint or spring element. It uses sensors to continuously monitor knee joint movement and walking phases, adjusting hydraulic resistance and knee motion accordingly. Patients enrolled in the registry will undergo baseline evaluation, fitting, training or therapy sessions, and follow-up visits at 6, 12, 24, and 36 months after fitting. Participants will be assessed through various tests including timed walk tests, balance confidence scores, and mobility assessments at different intervals. The study also tracks falls related to device use and changes in activity levels with an activity tracker. Data collected will help characterize the safety and functional impact of the C-Brace over three years of follow-up.

All AgesAll Genders
76 locations
C

Actively Recruiting

Healthy Volunteer

Many patients with severe and sometimes life-threatening symptoms remain undiagnosed despite extensive medical evaluations, leaving them and their families uncertain about their health and future. The Undiagnosed Diseases Program UDP and the subsequent Undiagnosed Diseases Network UDN were established by the National Institutes of Health to provide answers and care for these individuals. These programs aim to understand rare and undiagnosed conditions by collecting detailed clinical and genetic information and promoting collaboration across research centers. Participants undergo thorough clinical evaluations, including detailed phenotyping, genetic analyses, and functional studies of potential disease-causing variants. The testing involves both medically necessary studies, such as skin biopsies and blood draws, and research investigations that contribute to diagnosis efforts. The UDN allows sharing of identifiable phenotypic and genotypic data among network centers and de-identified data with external researchers to improve understanding and diagnosis of rare conditions. Throughout the study, participants provide medical history and biological samples, and undergo various tests to help reach a diagnosis. Researchers measure outcomes related to building a collaborative research community, investigating disease mechanisms, and improving diagnosis and care through standardized data collection and protocols. Participation can involve initial evaluations over several days and ongoing follow-up to advance knowledge and management of undiagnosed diseases.

Age: 1Month - 100YearsAll Genders
33 locations
U

Actively Recruiting

Central Line-Associated Bloodstream Infections CLABSIs are a serious problem in U.S. hospitals, leading to higher death rates, longer hospital stays, and increased costs. This research evaluates whether a machine learning ML model that predicts possible CLABSI risk can help Infection Preventionists IPs reduce infection rates compared to usual practices. The study is a prospective, multi-center, cluster-randomized trial conducted in 20 hospitals with the highest CLABSI rates. In this trial, hospitals are split into early and late groups. Early hospitals get access to the ML model via a daily dashboard that flags high-risk patients. Infection Preventionists use this information to provide targeted education and recommend best practices for central line care, including line removal when appropriate. The model was built using extensive patient data and predicts infection risk with high accuracy. The control hospitals continue with routine clinical practice without access to the model during the study period. Participants are hospitalized adults with central lines, and the model scores patients daily if their line has been in place for over 48 hours. Researchers monitor CLABSI rates per 1,000 central line-days, central line removals within 48 hours of alerts, positive blood culture rates, and IP intervention frequencies. Safety outcomes such as pneumothorax and hemorrhage are also tracked. The study duration is about five months with interim and final analyses planned to assess the impact of providing the ML model to Infection Preventionists.

Age: 18Years +All GendersPhase Not Applicable
19 locations
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
A

Actively Recruiting

Researchers are studying a new medicine called PF-08634404 to see how well it works in adults with metastatic colorectal cancer, which is cancer that has spread to other parts of the body. The study compares PF-08634404 combined with approved chemotherapy to an approved medicine called Bevacizumab combined with chemotherapy. The goal is to understand if the new medicine can improve outcomes for people whose cancer has spread or returned after previous treatments. Participants are randomly assigned to one of two treatment groups. One group receives PF-08634404 with chemotherapy, and the other group receives Bevacizumab with chemotherapy. All medicines are given through intravenous IV infusions at a clinical site. Treatment is given in cycles, and participants may continue treatment as long as it is helping and side effects are manageable. After treatment ends, participants return for a final visit around 30 to 37 days later. During the study, participants have regular visits for treatment, health checks, and tests. Follow-up continues every 12 weeks through phone, in-person visits, or health record reviews to monitor health status and any new treatments. Researchers will measure outcomes such as progression-free survival, overall survival, response rates, side effects, quality of life, and drug levels. The study is expected to last about 33 months per participant.

Age: 18Years +All GendersPhase 3
372 locations